Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.01−0.18 (-1.77%)
Close on Nov 19, 2026Market cap $842.05MP/E –Yield –
Corvus Pharmaceuticals gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for Corvus Pharmaceuticals
Corvus Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?